Current biological therapies have demonstrated excellent efficacy in PsA and have been shown to be safe agents.

The therapy of rheumatic diseases has undergone radical change in the last years with new biological therapies and the new evidence for these therapies is covered extensively.

For more than a decade, the U.S. has lavished funding on efforts to transform a wealth of biological breakthroughs in the lab into actual therapies and profits.